Targeting Immune-Fibroblast Crosstalk in Myocardial Infarction and Cardiac Fibrosis.
C-C chemokine receptor 2
fibroblast activator protein
fibrosis
heart failure
interleukin 1 beta
macrophages
Journal
Research square
Titre abrégé: Res Sq
Pays: United States
ID NLM: 101768035
Informations de publication
Date de publication:
26 Jan 2023
26 Jan 2023
Historique:
pubmed:
8
2
2023
medline:
8
2
2023
entrez:
7
2
2023
Statut:
epublish
Résumé
Inflammation and tissue fibrosis co-exist and are causally linked to organ dysfunction. However, the molecular mechanisms driving immune-fibroblast crosstalk in human cardiac disease remains unexplored and there are currently no therapeutics to target fibrosis. Here, we performed multi-omic single-cell gene expression, epitope mapping, and chromatin accessibility profiling in 38 donors, acutely infarcted, and chronically failing human hearts. We identified a disease-associated fibroblast trajectory marked by cell surface expression of fibroblast activator protein (FAP), which diverged into distinct myofibroblasts and pro-fibrotic fibroblast populations, the latter resembling matrifibrocytes. Pro-fibrotic fibroblasts were transcriptionally similar to cancer associated fibroblasts and expressed high levels of collagens and periostin (
Identifiants
pubmed: 36747878
doi: 10.21203/rs.3.rs-2402606/v1
pmc: PMC9900986
pii:
doi:
Types de publication
Preprint
Langues
eng
Déclaration de conflit d'intérêts
Competing Interests XL, TY, SS, AF, MF, C-ML and BA are or were employed by Amgen.